PM
NBRV

Prosight Management’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Prosight Management’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,686
Closed -$1.47M – 38
2018
Q2 		$1.47M Buy
1,686
+715
+74% +$819K 1.08% 23
2018
Q1 		$1.22M Sell
971
-995
-51% -$1.47M 0.77% 27
2017
Q4 		$2.94M Buy
+1,966
New +$3.11M 2.16% 19

Other funds holding NBRV

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $1.24B AUM 2.91% 1-Year Est. Return

Prosight Management's NBRV Position: Q3 2018 in Review

Prosight Management sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q3 2018, closing a stake of 1,686 shares — an estimated $1.47M sold.

Prosight Management first reported a position in NBRV in Q4 2017 and held it in 3 quarters. The position peaked at $2.94M in Q4 2017. 45 funds tracked by Wall St. Rank hold NBRV as of Q3 2018.

  • Prosight Management reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q3 2018 after selling out during the quarter.
  • Prosight Management sold 1,686 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q3 2018, an estimated $1.47M.
  • Prosight Management first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2017 and held it in 3 quarters.
  • Prosight Management's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $2.94M in Q4 2017.
  • 45 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q3 2018.

Based on Prosight Management's 13F filing for Q3 2018, filed 15 Nov 2018.